Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Amondys 45 Market Size And Revenue Outlook Through 2030
Historical expansion was driven by a scarcity of Duchenne muscular dystrophy treatment options, incentives for orphan drug development, the broadening scope of genetic testing, initial research into antisense technology, and the dedication of patient advocacy groups.
The expansion observed in the upcoming period is attributable to progress in gene-based treatments, more extensive newborn screening, the increased availability of exon-specific medications, consistent expedited regulatory processes, and a boost in clinical trial funding.
Significant patterns for the projected timeframe involve the rise of exon skipping treatments, the spread of precision genetic medicine, a greater emphasis on infrequent neuromuscular conditions, targeted interventions prompted by early detection, and growing regulatory assistance for orphan drugs.
Get A Free Sample Report With In-Depth Market Insights:
Amondys 45 Market Industry Drivers: What’s Behind The Revenue Growth?
The expanding occurrence of genetic conditions is anticipated to fuel the amondys 45 market in the future. A genetic condition is defined as a health issue stemming from irregularities in an individual’s DNA, potentially caused by single or multiple gene mutations, chromosomal alterations, or a combination of genetic and environmental elements. The upward trend in genetic disease prevalence is attributed to enhanced public understanding and breakthroughs in diagnostic tools, which facilitate earlier and more precise identification of previously undetected ailments. amondys 45 assists in addressing genetic disorders by focusing on particular dystrophin gene mutations, making it effective for Duchenne muscular dystrophy patients who require exon 45 skipping. It promotes better muscle performance by enabling the creation of a functional, albeit shorter, dystrophin protein, thereby aiding in decelerating disease progression and improving clinical results. For example, in July 2025, the National Blood Authority, an Australian blood management agency, noted 2,788 patients with hereditary haemophilia A (HMA) in 2023–2024, an increase from 2,681 patients in 2022–2023. Consequently, the increasing accessibility of genetic testing is propelling the growth of the amondys 45 market.
Amondys 45 Market Segments: Where Is Growth Concentrated?
The amondys 45 market covered in this report is segmented –
1) By Indication: Duchenne Muscular Dystrophy (DMD) – Exon 45 Mutation, Other Genetic Mutations
2) By End-User: Adult, Geriatric, Pediatric
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Amondys 45 Market Key Participants And Competitive Landscape
Major companies operating in the amondys 45 market are Sarepta Therapeutics Inc.
View The Full Amondys 45 Market Report:
Amondys 45 Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the amondys 45 market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the amondys 45 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model









